Relationship between heart failure treatment and development of worsening renal function among hospitalized patients - 26/08/11
, Daniel E Forman, MD b, William T Abraham, MD c, Stephen S Gottlieb, MD d, Evan Loh, MD e, Barry M Massie, MD f, Christopher M O'Connor, MD g, Michael W Rich, MD h, Lynne Warner Stevenson, MD i, Yongfei Wang, MS j, James B Young, MD k, Harlan M Krumholz, MD jAbstract |
Background |
Among patients who are hospitalized with heart failure (HF), worsening renal function (WRF) is associated with worse outcomes. Whether treatment for HF contributes to WRF is unknown. In this study, we sought to assess whether acute treatment for patients who were hospitalized with HF contributes to WRF.
Methods |
Data were collected in a nested case-control study on 382 subjects who were hospitalized with HF (191 patients with WRF, defined as a rise in serum creatinine level >26.5 μmol/L [0.3 mg/dL], and 191 control subjects). The association of medications, fluid intake/output, and weight with WRF was assessed.
Results |
Calcium channel blocker (CCB) use and loop diuretic doses were higher in patients on the day before WRF (25% vs 10% for CCB; 199 ± 195 mg vs 143 ± 119 mg for loop diuretics; both P <.05). There were no significant differences in the fluid intake/output or weight changes in the 2 groups. Angiotensin-converting enzyme (ACE) inhibitor use was not associated with WRF. Other predictors of WRF included elevated creatinine level at admission, uncontrolled hypertension, and history of HF or diabetes mellitus. Higher hematocrit levels were associated with a lower risk. Vasodilator use was higher among patients on the day before WRF (46% vs 35%, P <.05), but was not an independent predictor in the multivariable analysis.
Conclusions |
Several medical strategies, including the use of CCBs and a higher dose of loop diuretics, but not ACE inhibitors, were associated with a higher risk of WRF. Although assessment of inhospital diuresis was limited, WRF could not be explained by greater fluid loss in these patients. Determining whether these interventions are responsible for WRF or are markers of higher risk requires further investigation.
Le texte complet de cet article est disponible en PDF.Plan
 | Supported by Biogen, Inc, Cambridge, Mass. |
Vol 147 - N° 2
P. 331-338 - février 2004 Retour au numéro
Article précédent
- Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial
- Masatsugu Hori, Shigetake Sasayama, Akira Kitabatake, Teruhiko Toyo-oka, Shunnosuke Handa, Mitsuhiro Yokoyama, Masunori Matsuzaki, Akira Takeshita, Hideki Origasa, Kennichi Matsui, Saichi Hosoda, MUCHA Investigators
- Effects of a home walking exercise program on functional status and symptoms in heart failure
- Teresita Corvera-Tindel, Lynn V Doering, Mary A Woo, Steven Khan, Kathleen Dracup
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?